The Pradaxa Resource Center is the Webs largest source for information on Pradaxa legal news, research and side effects. Visit http://www.Pradaxa-lawsuits.org Dallas, TX (PRWEB) October 17, 2012 The news comes after an FDA warning on December 7, 2011 that it was investigating Pradaxa after receiving more injury or death reports than expected. USA Today reported on August 19th that the FDA received 3,781 reports of side effects and 542 deaths among Pradaxa users last year, leading all other medications in 2011. Now, a federal judge overseeing Pradaxa lawsuits filed by those injured has entered an order expediting the claim filing process. On October 4, 2012, Judge David Herndon entered a Case Management Order allowing for direct filing of claims into the Pradaxa Federal MDL. http://tinyurl.com/9dfgb6f Anyone affected by internal bleeding or the loss of a loved one after using Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible. Pradaxa is a popular blood thinner prescribed to prevent strokes and blood clots in patients with atrial fibrillation. According to The Wall Street Journal on April 24, 2012, Boehringer Ingelheim has earned more than $1 billion from the drug so far in more than 70 … Continue reading →

CHICAGO (Reuters) - An antibiotic used to treat severe bacterial infections showed promise at treating a highly drug-resistant and deadly form of tuberculosis, U.S. government and South Korean researchers said on Wednesday. The study, published in the New England Journal of Medicine, is the first scientifically rigorous clinical trial of Pfizer's antibiotic linezolid, or Zyvox, in patients with extensively drug-resistant TB (XDR-TB), which is resistant to at least four of the drugs most often used to treat the lung infection. Led by Clifton Barry of the National Institute of Allergy and Infectious Diseases and Sang-Nae Cho, professor of infectious diseases at Yonsei University, South Korea, the study showed the drug was effective when added to patients' current treatments. "The data that were reported are rather impressive," Dr. Anthony Fauci, director of the institute, a part of the National Institutes of Health, said in a telephone interview. However, most of the patients - 82 percent - experienced side effects while on the treatment, which tempered the findings, the team reported. "That is the bad news," Fauci said. "The somewhat encouraging news is that despite the toxicity, when the drug dose was decreased or was temporarily discontinued, the toxic side effects diminished … Continue reading →

Drug delivery research in India will advance with help from New Zealand, with the gift of a highly advanced qNano system to Prof. Rinti Banerjee from the Department of Biosciences & Bioengineering at the Indian Institute of Technology (IIT) in Mumbai. New Zealand nanotechnology company Izon Science gifted the instrument to accelerate advancement of research in the area of nanoparticles for drug delivery. . The gift recognises the path-breaking technology platform and drug delivery mechanism award winning Prof. Rinti Banerjee has developed. The qNano provides the highly accurate information required to aid development of drug delivery systems that could deliver cancer drugs directly to the tumor The qNano system was presented to Prof. Banerjee by Hans van der Voorn, the Executive Chairman of Izon Science. The function held at IIT Bombay was attended by Hon Steven Joyce, New Zealands Science and Innovation Minister, as part of his visit to India with a delegation of New Zealand education and aviation companies. Acting Director of IIT Bombay, Prof. R.K. Malik and Prof. N.S. Punekar, Head of Department of Biosciences & Bioengineering were also present at the occasion. Prof. Banerjee is the winner of numerous awards for her work including most recently the … Continue reading →

Fosamax Lawsuits Currently Pending in New Jersey Superior Court, Atlantic County, Involve Allegations that Long-Term Use of the Drug Caused Plaintiffs to Suffer Serious Fosamax Side Effects, Including Fosamax Femur Fractures and Osteonecrosis of the Jaw (ONJ) New York, New York (PRWEB) October 17, 2012 Fosamax Side Effects Fosamax is an oral bisphosphonate used to prevent fractures in people who have bone weakening diseases like osteoporosis and Pagets disease. In October 2010, the U.S. Food & Drug Administration (FDA) warned that people taking Fosamax and other bisphosphonates for osteoporosis are at risk of suffering atypical femur fractures.** Just this past May, an FDA-commissioned analysis published in the New England Journal of Medicine found that there was little benefit in taking Fosamax and similar drugs for longer than five years. The report cited serious Fosamax side effects, including femur fractures and ONJ.*** The Fosamax lawsuits currently pending in New Jersey involve both femur fractures and ONJ. In a letter dated, June 4, 2012, Judge Carol Higbee, who is overseeing the Fosamax side effects litigation, stated her intention to schedule bellwether trials for cases involving Fosamax femur fractures. Discovery for Fosamax femur fracture lawsuits is moving forward. Bernstein Liebhard LLP is actively … Continue reading →

NEW YORK (Reuters Health) - A drug approved to prevent seizures may also help obese people lose a few pounds when it's added to therapy and nutritional guidance, a new small trial suggests. But people who took zonisamide also reported more side effects, from nausea and vomiting to anxiety and depression. And two researchers not involved in the study questioned how much the drug would actually help people in the real world. Although zonisamide is only approved by the U.S. Food and Drug Administration for seizures, doctors can prescribe it "off-label" for non-approved purposes. Prior small trials and anecdotal evidence suggested it might help heavy people shed extra pounds. "There is a little bit of weight loss with this drug when it is given for treatment of epilepsy," said lead researcher Dr. Kishore Gadde, from Duke University Medical Center in Durham, North Carolina. That could be because of its effects on serotonin and dopamine, he said. Those two neurotransmitters are known to effect motivation and reward pathways in the brain, including those related to food. Gadde said his team wanted to see if zonisamide could produce weight loss in people without epilepsy, and with the added help of a behavioral … Continue reading →